Anti-VEGF Reference Antibody (bevacizumab)
产品介绍
产品性质
产品特色
应用案例
Purity:SDS-PAGE
Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Purity:SEC-HPLC
The purity of Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) is 97.8%, determined by SEC-HPLC.
Bioactivity:ELISA
Immobilized human VEGF165 His at 2 ug/mL can bind Anti-VEGF Reference Antibody (BioMab patent anti-VEGF), EC50=0.003018 ug/mL.
Research in vivo
Bevacizumab inhibited the tumor growth of COLO205 on balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 42.0% at 0.95 mpk at D31.
存储条件
-25~-15℃保存，有效期1年。
COA
相关产品
联系我们
